Subscription Center
Jun 30, 2009 | 3
How much are cancer drugs worth that may only prolong a patient’s life by a few weeks? It’s a pressing question given the rising cost of medicines, and one that a pair of National Institutes of Health researchers is urging cancer specialists to tackle now.
NIH’s Tito Fojo, who works on experimental cancer therapies, and Christine Grady, a bioethicist, call upon oncologists and the government to figure out when a costly cancer drug is worth prescribing and when it is not, saying, “We cannot ignore the cumulative costs of the tests and treatments we recommend and prescribe.”
The pair’s recent commentary in the Journal of the National Cancer Institute takes a look at drugs like Erbitux, a supplemental drug for the treatment of non-small cell lung cancer. Erbitux costs about $80,000 for 18 weeks of treatment, they write, while only prolonging life by an average of 1.2 months. The drug also carries side effects.
See what we're tweeting about
BecCrew RT @lukeayresryan Ridiculous – New York makes @airbnb illegal http://t.co/HfTcXRrlYt
jgold85 RT @avflox: The truth behind the hoax about the man who tried to have sex with a hornets nest: http://t.co/RoEXVQwrTx BecCrew RT @DCDeacon Have to see I haven't seen this disclaimer on a menu before. http://t.co/feS3FeyE3s
Deadline: Aug 31 2013
Reward: $100,000 USD
The Geoffrey Beene Foundation Alzheimer’s Initiative (GBFAI) is launching the 2013 Geoffrey Beene Global NeuroDiscovery Challenge whose
Deadline: Jun 29 2013
Reward: $7,000 USD
The Seeker for this Challenge desires proposals for chemical methods that could rapidly degrade a dilute aqueous solution
Powered By: 
YES! Send me a free issue of Scientific American with no obligation to continue the subscription. If I like it, I will be billed for the one-year subscription.
